Sequences

Sample result

A saved result, shown read-only. Sign in to run your own searches. A new account gets a free 30-day trial.

GLP-1, a diabetes hormone

Protein → Patent proteins · Automatic (Smith-Waterman)

Download as Excel

Every list and the search record, one sheet each.

Query
GLP-1 · 31 lettersHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
Set
Public patent sequences: Patent proteins, snapshot 2026-11-05-c456f6bdba29
Ran
2026-11-12
Found
5,000 sequences, 3,061 publications, 1,851 families

Charts

Identity against coverage

5,000 hits by identity and query coverage. 5,000 with a date.

Has a date707075758080858590909595100100Identity (%)Query coverage (%)
Show table
Hits by identity
BandHas a dateAll
100%553553
95 to 99.9%992992
90 to 94.9%2,6382,638
80 to 89.9%814814
70 to 79.9%33
Hits by query coverage
BandHas a dateAll
100%3,6063,606
95 to 99.9%876876
90 to 94.9%483483
80 to 89.9%3535

Hits by year

3,061 publications by year of first publication, 1990 to 2026.

Has a datePublications01002003001990199319961999200220052008201120142017202020232026
Show table
Publications by year of first publication
YearHas a dateAll
199022
199222
199311
199411
199511
199633
199722
199822
19991111
20001313
20012020
20023737
20033333
20043737
20055454
20066262
20077777
20088181
2009107107
2010101101
2011110110
2012121121
2013123123
2014135135
2015142142
2016144144
2017157157
2018149149
2019150150
2020156156
2021183183
2022161161
2023175175
2024181181
2025231231
20269696

Where hits align on the query

The top 20 hits on GLP-1, a query of 31 amino acids: 20 cover the whole query, none differs from it.

Aligned partDiffers from the queryGLP-1 · 31 amino acids151015202531HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGAAA55132.1A31422.1AAB11984.1DI506186DI527435AAB11995.1AAE02614.1DI540976DI521338DI502216DJ789879DI520483AAE49428.1AAE49430.1AAE49429.1AAE49432.1DI501808AAY78103.1BD613525BD613528
Show table
The top 20 hits on GLP-1, positions on the query
HitQuery fromQuery toIdentityDiffers atGaps atX at
AAA55132.1131100.0%NoneNoneNone
A31422.1131100.0%NoneNoneNone
AAB11984.1131100.0%NoneNoneNone
DI506186131100.0%NoneNoneNone
DI527435131100.0%NoneNoneNone
AAB11995.1131100.0%NoneNoneNone
AAE02614.1131100.0%NoneNoneNone
DI540976131100.0%NoneNoneNone
DI521338131100.0%NoneNoneNone
DI502216131100.0%NoneNoneNone
DJ789879131100.0%NoneNoneNone
DI520483131100.0%NoneNoneNone
AAE49428.1131100.0%NoneNoneNone
AAE49430.1131100.0%NoneNoneNone
AAE49429.1131100.0%NoneNoneNone
AAE49432.1131100.0%NoneNoneNone
DI501808131100.0%NoneNoneNone
AAY78103.1131100.0%NoneNoneNone
BD613525131100.0%NoneNoneNone
BD613528131100.0%NoneNoneNone

Patents 3.1K

Columns
Tick the columns each row shows, then choose Show. The arrows move a column.

3,061 publications from 692 applicants, 83 with no applicant, match these filters.

Eli Lilly and Company 205 publications, continued

  1. JP 2004521093-A2004-07-15

    CHRONIC TREATMENT REGIMEN USING GLUCAGON-LIKE INSULINOTROPIC PEPTIDES

    Eli Lilly and Company

    Query Match 93.8%Identity 96.7%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             | ||||||||||||||||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    29 of 30 identical, no gaps.

  2. US 7259233-A2007-08-21

    Chronic treatment regimen using glucagon-like insulinotropic peptides

    Eli Lilly and Company

    Query Match 93.8%Identity 96.7%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             | ||||||||||||||||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    29 of 30 identical, no gaps.

  3. EP 2186824-A22010-05-19

    Chronic treatment regimen using glucagon-like insulinotropic peptides

    Eli Lilly & Company (US)

    Query Match 93.8%Identity 96.7%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             | ||||||||||||||||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    29 of 30 identical, no gaps.

  4. US 7989585-B22011-08-02

    Chronic treatment regimen using glucagon-like insulinotropic peptides

    Eli Lilly and Company

    Query Match 93.8%Identity 96.7%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             | ||||||||||||||||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    29 of 30 identical, no gaps.

  5. JP 2005530732-A2005-10-13

    TREATMENT OF GASTROPARESIS

    Eli Lilly and Company

    Query Match 93.2%Identity 100.0%

    Best alignment

    Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
             |||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
    

    29 of 29 identical, no gaps.

  6. PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  7. US 11155592-B22021-10-26

    Protein tyrosine-tyrosine analogs and methods of using the same

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  8. JP 2022506070-A2022-01-17

    PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  9. JP 2023082013-A2023-06-13

    PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  10. US 11820803-B22023-11-21

    Protein tyrosine-tyrosine analogs and methods of using the same

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  11. PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  12. US 12269857-B22025-04-08

    Protein tyrosine-tyrosine analogs and methods of using the same

    Eli Lilly and Company

    Query Match 92.5%Identity 93.5%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| |||||||||||||||
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 31
    

    29 of 31 identical, no gaps.

  13. JP 2002532557-A2002-10-02

    Shelf-stable formulation of glucagon-like peptide-1

    ELI LILLY AND CO

    Query Match 90.1%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | |||||||||||| ||||| ||||||||||
    Hit    1 HXEGTFTSDVSSYLXGQAAKXFIAWLVKGRG 31
    

    28 of 31 identical, no gaps.

  14. EP 1600162-A12005-11-30

    Shelf-stable formulation of glucagon-like peptide-1

    Eli Lilly & Company (US)

    Query Match 90.1%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | |||||||||||| ||||| ||||||||||
    Hit    1 HXEGTFTSDVSSYLXGQAAKXFIAWLVKGRG 31
    

    28 of 31 identical, no gaps.

  15. Glp-1-fc fusion protein formulation

    ELI LILLY AND COMPANY (US)

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  16. GLP-1-FC FUSION PROTEIN FORMULATION

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  17. METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  18. JP 2020521765-A2020-07-27

    Therapeutic Uses of Dulaglutide

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  19. JP 2021502379-A2021-01-28

    Methods of Using and Compositions Containing Dulaglutide

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  20. THERAPEUTIC USES OF DULAGLUTIDE

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  21. JP 2022525883-A2022-05-20

    Preserved Formulations

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  22. THERAPEUTIC USES OF DULAGLUTIDE

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  23. METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  24. JP 2023002547-A2023-01-10

    Dulaglutide for the treatment of chronic kidney disease

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  25. JP 2023513054-A2023-03-30

    Therapeutic Uses of Dulaglutide

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  26. JP 2023123742-A2023-09-05

    Preserved Formulations

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  27. THERAPEUTIC USES OF DULAGLUTIDE

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  28. US 11890325-B22024-02-06

    Therapeutic uses of dulaglutide

    ELI LILLY AND COMPANY

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  29. JP 2025000602-A2025-01-07

    Therapeutic Uses of Dulaglutide

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  30. THERAPEUTIC USES OF DULAGLUTIDE

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  31. METHODS OF DULAGLUTIDE PURIFICATION USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY

    Eli Lilly and Company

    Query Match 88.2%Identity 90.3%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             | ||||||||||||| ||||||||||||| |
    Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
    

    28 of 31 identical, no gaps.

  32. EP 1227151-A12002-07-31

    Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

    ELI LILLY AND COMPANY (US)

    Query Match 87.6%Identity 96.6%

    Best alignment

    Query 2 to 30, hit 2 to 30. Positions start at 1 and include both ends.

    Query  2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             |||||||||||||||||| ||||||||||
    Hit    2 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 30
    

    28 of 29 identical, no gaps.

  33. US 6573237-A2003-06-03

    Protein formulations

    Eli Lilly and Company

    Query Match 87.6%Identity 100.0%

    Best alignment

    Query 2 to 30, hit 2 to 30. Positions start at 1 and include both ends.

    Query  2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             |||||||||||||||||| ||||||||||
    Hit    2 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 30
    

    28 of 29 identical, no gaps.

  34. Glp-1 pegylated compounds

    Eli Lilly and Company (US)

    Query Match 83.2%Identity 89.7%

    Best alignment

    Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
             | ||||||||||||| |||||||||| ||
    Hit    1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 29
    

    26 of 29 identical, no gaps.

  35. JP 2008540565-A2008-11-20

    GLP-1 Pegylated Compounds

    Eli Lilly and Company

    Query Match 83.2%Identity 89.7%

    Best alignment

    Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
             | ||||||||||||| |||||||||| ||
    Hit    1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 29
    

    26 of 29 identical, no gaps.

  36. US 8183340-B22012-05-22

    GLP-1 pegylated compounds

    Eli Lilly and Company

    Query Match 83.2%Identity 89.7%

    Best alignment

    Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
             | ||||||||||||| |||||||||| ||
    Hit    1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 29
    

    26 of 29 identical, no gaps.

  37. JP 2013079256-A2013-05-02

    GLP-1 Pegylated Compounds

    Eli Lilly and Company

    Query Match 83.2%Identity 89.7%

    Best alignment

    Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
             | ||||||||||||| |||||||||| ||
    Hit    1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 29
    

    26 of 29 identical, no gaps.

CARLSBERG LABORATORY 1 publication

  1. JP 2001513638-A2001-09-04

    Modified carboxypeptidase

    CARLSBERG LABORATORY

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    30 of 30 identical, no gaps.

ITOHAM FOODS INC 1 publication

  1. JP 2001278807-A2001-10-10

    Enterokinesis inhibitor

    ITOHAM FOODS INC

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 7 to 36. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    7 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 36
    

    30 of 30 identical, no gaps.

Theratechnologies Inc. (CA) 8 publications

  1. WO 0210195-A22002-02-07

    Modified peptides with increased potency

    THERATECHNOLOGIES INC. (CA)

    Query Match 100.0%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             |||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
    

    31 of 31 identical, no gaps.

  2. JP 2004509079-A2004-03-25

    MODIFIED BIOLOGICAL PEPTIDES WITH INCREASED POTENCY

    THERATECHNOLOGIES INC

    Query Match 100.0%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             |||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
    

    31 of 31 identical, no gaps.

  3. Modified glp-1 peptides with increased biological potency

    Theratechnologies Inc. (CA)

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    30 of 30 identical, no gaps.

  4. Compounds that modulate the glucagon response and uses thereof

    Theratechnologies Inc. (CA)

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    30 of 30 identical, no gaps.

  5. US 7067488-A2006-06-27

    Modified GLP-1 peptides with increased biological potency

    TheraTechnologies Inc.

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    30 of 30 identical, no gaps.

  6. EP 1709071-A12006-10-11

    Glucagon-like peptide-1 analogs with long duration of action

    THERATECHNOLOGIES INC

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    30 of 30 identical, no gaps.

  7. US 7538185-A2009-05-26

    Glucagon-like peptide-1 analogs with long duration of action

    Theratechnologies Inc.

    Query Match 96.3%Identity 100.0%

    Best alignment

    Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
             ||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
    

    30 of 30 identical, no gaps.

  8. Chemically modified metabolites of regulatory peptides and methods of producing and using same

    THERATECHNOLOGIES INC. (CA)

    Query Match 92.5%Identity 100.0%

    Best alignment

    Query 3 to 31, hit 1 to 29. Positions start at 1 and include both ends.

    Query  3 EGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             |||||||||||||||||||||||||||||
    Hit    1 EGTFTSDVSSYLEGQAAKEFIAWLVKGRG 29
    

    29 of 29 identical, no gaps.

Novo Nordisk A/S 299 publications

  1. JP 2002512175-A2002-04-23

    Derivatives of GLP-1 analogues

    NOVO NORDISK AS

    Query Match 100.0%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             |||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
    

    31 of 31 identical, no gaps.

  2. JP 2003520571-A2003-07-08

    Pectate lyase fusion for expression and secretion of polypeptides.

    Novo Nordisk A/S

    Query Match 100.0%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 348 to 378. Positions start at 1 and include both ends.

    Query   1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
              |||||||||||||||||||||||||||||||
    Hit   348 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 378
    

    31 of 31 identical, no gaps.

  3. JP 2003525908-A2003-09-02

    Lowering serum lipids

    Novo Nordisk A/S

    Query Match 100.0%Identity 100.0%

    Best alignment

    Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.

    Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
             |||||||||||||||||||||||||||||||
    Hit    1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
    

    31 of 31 identical, no gaps.